###begin article-title 0
Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 188 189 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 190 191 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 283 284 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 285 287 273 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Overactivation of nuclear factor kappaB (NF-kappaB) orchestrates airway eosinophilia, but does not dampen airway hyperresponsiveness in asthma. NF-kappaB repression by arsenic trioxide (As2O3) contributes to apoptosis of eosinophils (EOS) in airways. Here we provide evidence that As2O3 abrogates allergen (OVA)-induced airway eosinophilia by modulating the expression of IkappaBalpha, an NF-kappaB inhibitory protein, and decreases the airway hyperresponsiveness.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 8 14 <span type="species:ncbi:10090">murine</span>
Using a murine model of asthma, the airway hyperresponsiveness was conducted by barometric whole-body plethysmography. Airway eosinophilia, OVA-specific IgE in serum, and chemokine eotaxin and RANTES (regulated upon activation, normal T cell expressed and secreted) in bronchoalveolar lavage fluid were measured by lung histology, Diff-Quick staining, and ELISA. Chemokine-induced EOS chemotactic activity was evaluated using EOS chemotaxis assay. Electrophoretic mobility shift assay and Western blot analysis were performed to assess pulmonary NF-kappaB activation and IkappaBalpha expression, respectively.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 265 266 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 267 269 255 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 319 327 307 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 345 346 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 347 349 335 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 427 435 <span type="species:ncbi:405018">cardinal</span>
As2O3 attenuated the allergen-induced serum IgE, chemokine expression of eotaxin and RANTES, and the EOS recruitment in bronchoalveolar lavage fluid, which is associated with an increased IkappaBalpha expression as well as a decreased NF-kappaB activation. Also, As2O3 suppressed the chemotaxis of EOS dose-dependently in vitro. Additionally, As2O3 significantly ameliorated the allergen-driven airway hyperresponsiveness, the cardinal feature underlying asthma.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 177 178 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 179 181 175 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
These findings demonstrate an essential role of NF-kappaB in airway eosinophilia, and illustrate a potential dissociation between airway inflammation and hyperresponsiveness. As2O3 likely exerts its broad anti-inflammatory effects by suppression of NF-kappaB activation through augmentation of IkappaBalpha expression in asthma.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Asthma is now accepted as a T-helper type 2 (Th2) lymphocyte-mediated chronic inflammatory disorder, characterized by airway eosinophilia and airway hyperresponsiveness (AHR) [1]. Eosinophils (EOS) appear to play a crucial role in the ongoing inflammation due to either an impaired clearance or a delayed apoptosis in the airways, where accumulation of a number of EOS cytotoxic proteins including major basic protein, cationic proteins and peroxidase could occur [2]. Existing data support the notion that morphologic changes in airway tissue to the development and severity of AHR in asthma correlates with the presence of activated airway inflammatory cells, in particular EOS [3].
###end p 11
###begin p 12
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 813 814 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 952 953 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1224 1225 1172 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
The molecular regulatory pathways in induction of chronic cytokine expression and recruitment/activation of inflammatory cells in asthma remain elusive. However, there is growing recognition that these processes involve increased transcription of inflammatory genes via transcription factors [4]. One such transcription factor, nuclear factor kappaB (NF-kappaB), is abundant of p50 (NF-kappaB1)/p65 (RelA) heterodimer. In a latent state, NF-kappaB is sequestered as an inactive trimer by complexing with IkappaBalpha, a 37 kDa inhibitory protein, which promotes cytoplasmic retention and maintains a low basal transcriptional activity. IkappaBalpha consists of an N-terminal domain containing specific phosphorylation sites, five ankyrin repeat sequences, and a C-terminal domain of Pro-Glu-Ser-Thr polypeptides [5]. Upon stimulation, IkappaBalpha is phosphorylated by the IkappaB kinase, ubiquitinated and degraded through the 26S proteasome pathway [6]. Subsequently, the nuclear localization sequence of NF-kappaB is unmasked to allow its translocation into the nucleus, where it binds to DNA and initiates transcription of a wide range of NF-kappaB-dependent genes in association with immune and inflammatory responses [7].
###end p 12
###begin p 13
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 162 163 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 365 366 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 367 369 367 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 795 796 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 797 799 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 836 837 832 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 838 839 834 835 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1003 1005 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1056 1057 1048 1049 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1058 1060 1050 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1315 1316 1291 1292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1317 1318 1293 1294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
###xml 1132 1138 <span type="species:ncbi:10090">murine</span>
Arsenic compound has long been considered as a protoplasmic poison that can bind to human sulfydryl-containing proteins with high affinity. Arsenic trioxide (As2O3), extracted from arsenic compound, is a powerful ancient medication for a variety of ailments with the principle of "using a toxic against another toxic" in traditional Chinese medicine. Strikingly, As2O3 treatment in a regime of 10 mg/d of intravenous infusion for 28 to 60 days is effective in patients with acute promyelocytic leukemia (APL) without viable toxicity in refractory to the all-trans retinoic acid (ATRA) and the conventional chemotherapy by inducing apoptosis of APL cells [8]. Many studies have demonstrated that NF-kappaB overactivation underlines the chronicity of airway inflammation characteristic of asthma [9-12]. Recently, we have reported that As2O3-mediated NF-kappaB repression in airways facilitated EOS apoptosis in a dose-dependent manner, contributing to the resolution of airway eosinophilic inflammation [13]. In this study, we investigated the effects of As2O3 on allergen-induced AHR and NF-kappaB-mediated airway inflammation in a murine model of asthma. Our data indicate that inhibition of NF-kappaB activation through induction of IkappaBalpha expression may account for the broad anti-inflammatory action of As2O3.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Asthma modeling
###end title 15
###begin p 16
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 285 291 <span type="species:ncbi:10090">murine</span>
Specified pathogen-free female BALB/c mice, aged 6 to 8 weeks, were provided by the Chinese Academy of Medical Sciences (Beijing, China). The animal experiment was approved by Nanjing Medical University according to the guidelines of the Institutional Animal Care and Use Committee. A murine asthma model was established as described previously [14] with minor modifications.
###end p 16
###begin p 17
###xml 461 462 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 463 465 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 70 77 <span type="species:ncbi:9031">chicken</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
On days 0 and 7, mice received intraperitoneal injection of 20 mug of chicken ovalbumin (OVA, Grade V, Sigma-Aldrich, St. Louis, MO) adsorbed to 20 mg of aluminum hydroperoxide gel (Pierce, Rockford, IL). On days 14, mice were randomized to receive aerosol challenge with either 6% OVA in phosphate-buffered saline (PBS) or PBS alone via a nebula (1-5 muM particles, Bohringer Ingelheim, Germany) for 40 min per day up to 7 days. During the treatment period, As2O3 (Yida Pharmaceutics, Harbin, China) at dose of 0.5-4.5 mg/kg, dexamethasone (Dex, Phoenix Pharmaceutics, Belmont, CA) at dose of 2.5 mg/kg or PBS alone was injected into the peritoneum 30 min before each airway challenge. After the last aerosol exposure, mice were sacrificed at designated timepoints.
###end p 17
###begin title 18
Airway physiology
###end title 18
###begin p 19
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 309 313 309 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">enh </sub>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 318 319 318 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">e</sub>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 325 326 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">r</sub>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 337 339 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ef</sub>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 343 345 343 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">if</sub>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 355 359 355 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">enh </sub>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 378 380 378 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">e </sub>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 406 408 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">r </sub>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 434 437 434 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ef </sub>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 475 478 475 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">if </sub>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
Baseline resistance and AHR induced by nebulized methacholine (Sigma-Aldrich, St. Louis, MO) at dose of 12.5-100 mg/ml in conscious unrestrained-mice were assessed using barometric whole-body plethysmography (Buxco Electronics Inc., Troy, NY) as described previously [15]. Airway resistance is expressed as: Penh = [(Te/0.3 Tr)-1] x [2 Pef/3 Pif], where Penh = enhanced pause, Te = expiratory time (sec), Tr = relaxation time (sec), Pef = peak expiratory flow (ml/sec), and Pif = peak inspiratory flow (ml/sec).
###end p 19
###begin title 20
Bronchoalveolar lavage
###end title 20
###begin p 21
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Four hours after the last airway challenge, mice underwent euthanasia and were cannulated in the trachea. The lungs were washed twice with 1 ml aliquots of PBS to collect the bronchoalveolar lavage fluid (BALF). Subsequently, the lungs were removed, quickly frozen in liquid nitrogen, and stored at -70degreesC. Additionally, the lungs were collected at 1, 12, and 24 hrs post the last airway challenge to study the kinetics of pulmonary NF-kappaB activation.
###end p 21
###begin title 22
Lung histology
###end title 22
###begin p 23
Paraffin embedded lung sections (5 mum) collected 24 hrs after airway challenge were stained with hemotoxylin & eosin (Sigma-Aldrich, St. Louis, MO) for examination of histology.
###end p 23
###begin title 24
Diff-Quick staining
###end title 24
###begin p 25
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 79 81 79 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
Diff-Quick staining is a modified Wright's staining [16]. Centrifuged at 300 x g for 10 min, the pelleted cells of BALF were suspended in a serum-free RPMI 1640 medium. The cell viability, evaluated by the trypan blue exclusion method, was over 95%. Total and differential cell counts were enumerated on cytospins (Thermo Shandon, Pittsburgh, PA) in compliance with the Diff-Quick staining profile (Merck, Germany) by counting at least 200 to 500 cells in cross-section.
###end p 25
###begin title 26
Enzyme-linked immunosorbant assay (ELISA)
###end title 26
###begin p 27
###xml 474 477 472 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 339 350 <span type="species:ncbi:3704">horseradish</span>
###xml 379 384 <span type="species:ncbi:9940">sheep</span>
Serum levels of OVA-specific immunoglobulin E (IgE) were analyzed by ELISA using samples collected 24 hrs after the last OVA challenge. Briefly, 96-well plates were coated with either purified anti-mouse IgE (5 mug/ml, BD PharMingen, San Diego, CA) or OVA (100 mug/ml). After addition of serum samples, OVA-specific IgE was detected using horseradish peroxidase (HRP)-conjugated sheep anti-IgG (Calbiochem, La Jolla, CA). Arbitrary units (AU) were calculated according to OD50 of the standard curve.
###end p 27
###begin p 28
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine chemokines, eotaxin and RANTES (regulated upon activation, normal T cell expressed and secreted), in the BALF samples were measured by utilizing paired antibodies following the manufacturer's recommendations. The ELISA kits were purchased from R&D Systems (Minneapolis, MN) with a minimum detectable levels of 3 and 5 pg/ml for eotaxin and RANTES, respectively.
###end p 28
###begin title 29
EOS chemotaxis assay (ECA)
###end title 29
###begin p 30
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 566 567 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 568 570 567 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 19 34 <span type="species:ncbi:10090">transgenic mice</span>
###xml 209 224 <span type="species:ncbi:10090">transgenic mice</span>
###xml 344 347 <span type="species:ncbi:10116">rat</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
Interleukin (IL)-5 transgenic mice (CBA/CaH-TnN) were provided by the Institute of Chemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). EOS (~98% purity) were derived from spleen of IL-5 transgenic mice with depletion of B, T, and antigen-presenting cells using anti-B220, anti-CD4, anti-CD8 and anti-class II, as well as rat anti-mouse Ig-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA) as described previously [17]. EOS were seeded at 5 x 104 density in triplicate and preincubated for 15 min at room temperature with 0.25-2 muM of As2O3 prior to chemotaxis measurement.
###end p 30
###begin p 31
###xml 448 449 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 364 370 <span type="species:ncbi:9913">bovine</span>
Chemotaxis was assessed in 48-well micro-Boyden chambers using polyvinylpyrrolidone-free polycarbonate membranes (NeuroProbe, Bethesda, MD). Cell suspension and diluted chemokines of eotaxin or RANTES (PeproTech, London, UK) were added into the chamber with RPMI 1640 containing 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acids (HEPES, pH 7.4) and 0.05% bovine serum albumin. The plates were incubated for 60 min at 37degreesC under 5% CO2. The migrated cells were counted in five randomly selected high-power fields (magnification was x 1,000). Spontaneous migration was evaluated in the absence of chemoattractant.
###end p 31
###begin title 32
Extraction of nuclear and total proteins
###end title 32
###begin p 33
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 241 242 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 385 387 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 503 504 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 740 742 732 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
Nuclear and total proteins of lung tissue were collected as described previously [18]. Briefly, aliquots of liquid nitrogen-frozen tissue were pulverized and lysed in 200 mul of cold Buffer A [10 mM Tris-HCl (pH7.5), 150 mM NaCl, 1.5 mM MgCl2, 0.65% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and 0.5 mM dithiothreitol (DTT)] for 3 min. After centrifugation at 10,000 x g for 1 min at 4degreesC, the nuclear pellets were extracted with 20 mul of Buffer B [20 mM HEPES (pH7.9), 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM DTT, 0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM PMSF and 25% glycerol] for 30 min with intermittent mixing on ice. The supernatant containing nuclear proteins was collected by centrifugation at 12,000 x g for 5 min.
###end p 33
###begin p 34
The total proteins were prepared by addition of Buffer A to the lung powder and subjected to two freeze/thaw cycles to fracture the nuclear membranes. After centrifugation, the supernatant was collected. The nuclear and total proteins were quantitated using the Bradford assay (BioRad, Hercules, CA), aliquoted and stored at -70degreesC until use.
###end p 34
###begin title 35
Electrophoretic mobility shift assay (EMSA)
###end title 35
###begin p 36
###xml 124 134 124 134 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGGACTTTCC</underline>
###xml 228 230 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 469 471 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
EMSA analysis was performed using a commercial kit (Promega, Madison, WI). Double-stranded oligonucleotide probe (5'-AGTTGAGGGGACTTTCCCAGGC-3') containing a consensus NF-kappaB sequence (underlined) was end-labelled with [gamma-32P]-adenosine triphosphate (Furui Biotechnology, Beijing, China) by T4 polynucleotide kinase and purified by chromatography. The binding reaction was conducted in a final volume of 20 mul containing 5 mug of nuclear proteins and 30 fmol of 32P-labelled oligonucleotide probe. Protein-DNA complexes were separated by electrophoresis on a 5% native polyacrylamide gel (37:1 acrylamide:bis-acrylamide) in a 0.5 x Tris-borate-EDTA running buffer. The dried gel was exposed to PhosphorImager (Molecular Dynamics) using ImageQuant software (Amersham Life Science, Arlington Heights, IL).
###end p 36
###begin p 37
For competition assay, a 100-fold excess of unlabelled NF-kappaB or activator protein 1 (AP-1) oligonucleotide probe was added to the reaction mixture 10 min before addition of the labelled probe. For supershift assay, a 0.5 mug of anti-p50 or anti-p65 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the reaction mixture prior to the labelled probe for 30 min.
###end p 37
###begin title 38
Western blot analysis
###end title 38
###begin p 39
###xml 490 494 <span type="species:ncbi:9925">goat</span>
###xml 500 506 <span type="species:ncbi:9986">rabbit</span>
Denatured samples (100 mug of total proteins) were fractionated by 10% sodium dodecyl sulfate polyacrylamide gel eletrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Blots were blocked with 5% milk containing 1 x TBST [40 mM Tris-HCl (pH7.6), 300 mM NaCl and 0.1% Tween-20] at 4degreesC overnight. Thereafter the blot was probed with primary antibodies of anti-IkappaBalpha (1:1,000 dilution) or anti-beta-actin antibody (1:800 dilution) for 1 hr. After an HRP-conjugated goat anti-rabbit IgG (1:5,000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA) incubation, the immunoblots were visualized by an enhanced chemiluminescence (ECL) kit (Pierce, Rockford, IL) according to the manufacture's instructions.
###end p 39
###begin title 40
Data analysis
###end title 40
###begin p 41
###xml 79 81 79 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q </italic>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pearson </italic>
Statistical analysis was performed by one-way analysis of variance (ANOVA) and q test with SPSS 11.0 software package (SPSS Inc., Chicago, IL). The negative relationship was evaluated by Pearson correlation analysis. Data were expressed as mean +/- SEM, and p < 0.05 was considered statistically significant.
###end p 41
###begin title 42
Results
###end title 42
###begin title 43
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Attenuation of airway EOS recruitment by As2O3
###end title 43
###begin p 44
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 307 309 307 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 673 674 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 675 677 675 677 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B&#8211;C</xref>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1251 1252 1251 1252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1253 1254 1253 1254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1346 1350 1346 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A&#8211;C</xref>
###xml 1358 1359 1358 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 1095 1099 <span type="species:ncbi:10090">mice</span>
###xml 1148 1152 <span type="species:ncbi:10090">mice</span>
###xml 1202 1206 <span type="species:ncbi:10090">mice</span>
###xml 1325 1329 <span type="species:ncbi:10090">mice</span>
OVA-challenged mice in response to 0.5-4.5 mg/kg of As2O3 reduced the number of EOS in BALF in a dose-dependent manner (Fig. 1). Since the anti-inflammatory effects of As2O3 were similar at the doses of 4 and 4.5 mg/kg, and it was comparable to the effect of 2.5 mg/kg of Dex (p > 0.05), the 4 mg/kg of As2O3 was herein chosen as the effective dosage in the rest of experiments. This dosage was also proved to be relatively safe based on our previous experiments [13,14]. Histological analysis of the OVA-challenged mice lung revealed an enhanced airway eosinophilia as compared to the naive control mice that were treated with PBS (Fig. 2A). Conversely, pretreatment of As2O3 protected mice from developing the allergen-induced peribronchial inflammation (Fig. 2A). Examination of BALF collected from mice at 24 hrs after OVA challenge showed a marked influx of inflammatory cells into the airways, including EOS, lymphocytes, macrophages and neutrophils (Fig. 2B-C). The increased EOS in the BALF was correlated with an increase of EOS recruitment by the Diff-Quick analysis in OVA-challenged mice (Fig. 2B). The number of EOS in BALF from naive mice was less than 1%, whereas that of OVA-challenged mice was about 49% (p < 0.01). Pretreatment of As2O3 dramatically attenuated the airway eosinophilia in the OVA-challenged mice (p < 0.01; Fig. 2A-C; Table 1).
###end p 44
###begin p 45
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>decreases EOS recruitment in BALF in a dose-dependent manner</bold>
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 208 210 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 492 494 490 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 515 518 513 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 536 550 534 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225; </sup>
###xml 560 567 546 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 577 580 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
As2O3 decreases EOS recruitment in BALF in a dose-dependent manner. Intraperitoneal administration of OVA-challenged mice with As2O3 (0.5-4.5 mg/kg) reduced the EOS in BALF, in which both 4, 4.5 mg/kg of As2O3 and 2.5 mg/kg of Dex achieved the similar anti-inflammatory effects. BALF EOS, stained with Diff-Quick solution, were counted using a hematocytometer, and expressed as a percentage in total leukocytes. Data represent the mean +/- SEM of four separate experiments (n = 6 per group). # p < 0.05, *p < 0.01, vs the control mice; double dagger p < 0.05, dagger p < 0.01, vs the OVA-challenged mice.
###end p 45
###begin p 46
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>markedly ameliorates allergic airway inflammation</bold>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 653 655 651 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 677 680 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 698 705 696 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 715 718 708 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
As2O3 markedly ameliorates allergic airway inflammation. (A) Lung tissues of naive mice, untreated OVA-challenged mice, and OVA-challenged mice treated with 4 mg/kg of As2O3 were subjected to histological analysis by staining with hematoxylin & eosin. Magnification was x 400. (B) BALF was collected 24 hrs after the final OVA challenge, and stained with Diff-Quick for microscopic detection of EOS dyed in orangeophil red with cytoplasmic acidophil granules (arrows). Magnification was x 200. (C) Total and differential cell counts in BALF are plotted for each group. Data represent the mean +/- SEM of three independent experiments (n = 6 per group). # p < 0.05, * p < 0.01, vs the control mice; dagger p < 0.01, vs the OVA-challenged mice.
###end p 46
###begin p 47
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Effect of As2O3 on EOS recruitment in BALF (%), pulmonary NF-kappaB activity (relative intensity units) and IkappaBalpha expression (IkappaBalpha/beta-actin).
###end p 47
###begin p 48
###xml 83 85 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 107 110 105 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 128 135 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 145 148 138 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Data represent the mean +/- SEM of four independent experiments (n = 6 per group). # p < 0.05, * p < 0.01, vs the control mice; dagger p < 0.01, vs the OVA-challenged mice at 4 hrs.
###end p 48
###begin title 49
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Amelioration of AHR by As2O3
###end title 49
###begin p 50
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1 4 1 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">enh</sub>
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 115 118 115 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">enh</sub>
###xml 335 336 335 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 337 339 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 163 167 <span type="species:ncbi:10090">Mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
Penh, relative to the measured airway resistance, was obtained as an index and was normalized to the postsaline - Penh. This readout was used as a measure of AHR. Mice previously sensitized and challenged with OVA developed a dose-dependent methacholine-induced bronchospasm as compared to the naive mice that were treated with PBS. As2O3 treatment significantly reduced the effect (p < 0.01; Fig. 3).
###end p 50
###begin p 51
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>prohibits allergen-induced AHR</bold>
###xml 362 363 362 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 364 365 364 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 450 452 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 474 477 472 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 38 42 <span type="species:ncbi:10090">Mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
As2O3 prohibits allergen-induced AHR. Mice were placed in whole-body plethysmographs and underwent varying methacholine challenge 24 hrs after the last airway challenge of OVA or PBS. The OVA-challenged mice exhibited remarkable bronchial reactivity to inhaled methacholine, compared with control mice or mice challenged with OVA in the presence of 4 mg/kg of As2O3. Data represent the mean +/- SEM of four independent experiments (n = 5 per group). # p < 0.05, * p < 0.01, vs the control or OVA-challenged mice.
###end p 51
###begin title 52
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Reduction of serum IgE and BALF chemokines by As2O3
###end title 52
###begin p 53
###xml 235 236 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 237 239 237 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 635 637 635 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
IgE can augment allergic airway responses in a high affinity receptor-dependent manner. Serum levels of OVA-specific IgE were elevated in OVA-challenged mice compared with the naive control mice (p < 0.01), whereas pretreatment with As2O3 resulted in a 4.8-fold decrease to the levels of the OVA mice (p < 0.01; Fig. 4A). Eotaxin and RANTES play a critical role in inducing chemotaxis of EOS [19]. ELISA analysis showed that levels of eotaxin and RANTES in BALF were markedly increased in OVA-challenged mice in comparison with the control mice (p < 0.01). However, these chemokine levels were largely reduced by pretreatment with As2O3 (p < 0.05 or 0.01; Fig. 4B).
###end p 53
###begin p 54
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>alleviates OVA-specific IgE in serum and eotaxin and RANTES in BALF of allergen-sensitized mice</bold>
###xml 363 365 361 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 387 390 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 408 415 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 425 428 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
As2O3 alleviates OVA-specific IgE in serum and eotaxin and RANTES in BALF of allergen-sensitized mice. Serum and BALF were collected 24 hrs after the last OVA challenge. Levels of (A) OVA-specific IgE in serum and (B) chemokine eotaxin and RANTES in BALF were analyzed by ELISA. Data represent the mean +/- SEM of three independent experiments (n = 6 per group). # p < 0.05, * p < 0.01, vs the control mice; dagger p < 0.01, vs the OVA-challenged mice.
###end p 54
###begin title 55
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Ablation of EOS chemotaxis by As2O3
###end title 55
###begin p 56
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">0</sup>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 194 195 194 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 196 198 196 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Eotaxin and RANTES with respective concentrations of 1 (100) and 103 nM reached a maximal chemotaxis response indicating that eotaxin is a more active chemotaxin to EOS than RANTES (Fig. 5A). As2O3 significantly inhibited the EOS chemotaxis mediated by eotaxin or RANTES in a dose-dependent manner (p < 0.05 or 0.01; Fig. 5B).
###end p 56
###begin p 57
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>ablates EOS chemotaxis</bold>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 256 258 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 482 484 480 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 506 509 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 537 544 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 554 557 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
As2O3 ablates EOS chemotaxis. (A) Eotaxin and RANTES induced chemotaxis of EOS, in which eotaxin was more potent than RANTES. The numbers of migrating cells per five high-power fields (magnification was x 1,000) are shown. (B) Pretreatment of EOS with As2O3 15 min before transferring to the chemotaxis chamber greatly suppressed the eotaxin or RANTES-induced migration in a dose-dependent manner. Data represent the mean +/- SEM of three independent experiments (n = 5 per group). # p < 0.05, * p < 0.01, vs the control (medium alone); dagger p < 0.01, vs the prestimulation with medium plus stimulation with 1 nM of chemokines.
###end p 57
###begin title 58
###xml 50 51 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 52 53 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Inhibition of pulmonary NF-kappaB activation by As2O3
###end title 58
###begin p 59
###xml 386 387 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 388 390 380 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 406 407 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 445 446 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 900 901 872 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
The OVA challenged mice showed a sharp increase in the pulmonary DNA binding activity of NF-kappaB at various timepoints as compared to the unchallenged mice lung. Indeed, NF-kappaB activity was increased within 1 hr (p < 0.01), peaked at 4 hrs (p < 0.01), and decreased by 12 (p < 0.01) to 24 hrs (p < 0.05). This effect of OVA challenge was clearly ameliorated by pretreatment with As2O3 (p < 0.01; Fig. 6, lane 6 as compared to lane 3; Table 1). In the competition assay, addition of 100-fold excess of unlabelled NF-kappaB, but not AP-1, oligonucleotide probe competed away the NF-kappaB-DNA complexes, verifying the specificity of NF-kappaB binding. In the supershift assay, addition of antibodies against p50 and p65 resulted in retardation of supershifted bands, with reciprocal decreases in the intensity of the NF-kappaB bands, confirming the classic subunits of NF-kappaB heterodimer (Fig. 6).
###end p 59
###begin p 60
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 83 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>inhibits pulmonary NF-&#954;B activation in OVA-sensitized and challenged mice</bold>
###xml 185 191 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 213 222 205 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lanes 2&#8211;5</italic>
###xml 296 302 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 6</italic>
###xml 339 340 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 341 343 333 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 379 389 371 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Lanes 7&#8211;8</italic>
###xml 441 451 433 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lanes 9&#8211;10</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
As2O3 inhibits pulmonary NF-kappaB activation in OVA-sensitized and challenged mice. Nuclear extracts of lung tissue were prepared and subjected to EMSA analysis of NF-kappaB activity. Lane 1: Naive control mice; Lanes 2-5: OVA-sensitized mice 1, 4, 12, and 24 hrs after the final OVA challenge; Lane 6: OVA-sensitized mice treated with As2O3 4 hrs after the final OVA challenge; Lanes 7-8: Specific (cold) and nonspecific (NS) competition; Lanes 9-10: Supershifts of p50 and p65. Nuclear extracts of lanes 7 to 10 were derived from those of lane 3. Free DNA probe is not shown. The arrows indicate the specific NF-kappaB-DNA complexes, p50 dimer, and supershifts, respectively. One of four independent experiments is shown.
###end p 60
###begin title 61
###xml 55 56 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 57 58 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Augmentation of pulmonary IkappaBalpha expression by As2O3
###end title 61
###begin p 62
###xml 121 122 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 130 131 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 194 195 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 196 198 188 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 404 406 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
The pulmonary IkappaBalpha expression in the lung lysate was relatively decreased in OVA-challenged mice (p < 0.01; Fig. 7; Table 1) compared to the control lung. In contrast, pretreatment of As2O3 accumulated the pulmonary IkappaBalpha (p < 0.01). Furthermore, there was a tight negative correlation between EOS recruitment in the BALF or the pulmonary NF-kappaB activation and IkappaBalpha expression (r = -0.82 and -0.94, respectively; p < 0.01).
###end p 62
###begin p 63
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 86 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">As<sub>2</sub>O<sub>3 </sub>augments pulmonary I&#954;B&#945; expression in OVA-sensitized and challenged mice</bold>
###xml 275 281 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1</italic>
###xml 303 309 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 2</italic>
###xml 347 353 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane 3</italic>
###xml 416 417 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 418 419 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
As2O3 augments pulmonary IkappaBalpha expression in OVA-sensitized and challenged mice. Total proteins of lung tissue were extracted 4 hrs after the final OVA challenge, and subjected to Western blot analysis of IkappaBalpha. beta-Actin was utilized as the standard control. Lane 1: Naive control mice; Lane 2: OVA-sensitized and challenged mice; Lane 3: OVA-sensitized and challenged mice treated with 4 mg/kg of As2O3. The positions of molecular size standards (in kDa) are indicated by arrows. One of three separate experiments is shown.
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 81 83 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 572 574 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 694 696 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 747 749 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1103 1105 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1106 1108 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Multiple upstream signal events converge on the NF-kappaB-inducing kinase (NIK) [20]. Activation of NIK results in phosphorylation of IkappaB kinases, which render the phosphorylation of IkappaBalpha at N-terminal serines 32 and 36 (Ser32 and Ser36) residues, leading to a proteolytic degradation of IkappaBalpha. Consequently, the activated NF-kappaB translocates to the nucleus, where it bonds to specific kappaB sites to facilitate the transcription of target genes. This results in expression of numerous pro-inflammatory cytokines, chemokines and adhesion molecules [21]. These pro-inflammatory mediators are essential in the recruitment of airway inflammatory cells, including EOS and CD4+ T lymphocytes, which in turn secret Th2 cytokines [22]. Therefore, NF-kappaB repression in airways via suppression of IkappaBalpha degradation or augmentation of IkappaBalpha synthesis would decrease the transcription of a myriad of NF-kappaB-dependent genes. This strategy proved to be more effective than that of blocking a single downstream inflammatory or an immune gene among the inflammatory cascade [23,24].
###end p 65
###begin p 66
###xml 217 219 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 361 363 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 472 474 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 596 598 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 868 870 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1231 1233 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1234 1236 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 755 763 <span type="species:ncbi:405018">cardinal</span>
Several lines of evidence suggest a central role of NF-kappaB in the pathogenesis of asthma. Activated NF-kappaB has been identified in sputum-induced macrophages and bronchial biopsy specimens of asthmatic patients [25]. Agents such as allergens, ozone and viral infections, which are associated with exacerbation of asthma, stimulate activation of NF-kappaB [26]. As the major effective treatment for asthma, glucocorticoids are potent blockers of NF-kappaB activation [27]. Furthermore, mice lacking the NF-kappaB subunits p50 or c-Rel develop less airway inflammation upon antigen challenge [28]. Nevertheless, NF-kappaB activation orchestrates allergen-induced inflammation and subsequent adaptive responses, but does not appear to modulate AHR, the cardinal feature that underlies asthma, signifying a potential dissociation between airway inflammation and AHR [29]. Clearly, additional airway signaling pathways activated, residual NF-kappaB activity or other inflammatory processes may be responsible for the AHR. Alternatively, events localized more distally within the alveolar compartments, such as microvasculature leakage of macromolecules, alveolar injury or surfactant dysfunction might dominate the genesis of AHR [30-32].
###end p 66
###begin p 67
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 69 78 68 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 135 143 134 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 144 145 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 250 252 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 253 255 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 371 372 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 373 375 368 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 470 471 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 472 474 467 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 538 540 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 678 680 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 736 737 727 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 738 740 729 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 952 954 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 955 957 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 971 972 958 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 973 975 960 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1246 1248 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1249 1251 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1296 1297 1267 1268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1298 1300 1269 1271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1390 1392 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1429 1430 1400 1401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1431 1433 1402 1404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
As2O3 (1-2 muM) induces the apoptosis in t (15;17) APL cell line NB4 in vitro and in APL patients without significant myelosuppression in vivo [8]. We and others have confirmed that inhibition of NF-kappaB was essential to arsenic-induced apoptosis [13,33]. In this report, despite a decreased serum OVA-specific IgE production, we demonstrated an inhibitory effect of As2O3 on EOS recruitment from OVA-challenged BALF, in agreement with our previous observation that As2O3 promoted EOS apoptosis in the airway eosinophilic inflammation [13]. Additionally, both eotaxin and RANTES, downstream genes of NF-kappaB, demonstrated potent chemoattractants to EOS and Th2 lymphocytes [34]. Presumably, the ablation of airway eosinophilia by As2O3 results from a collective effects of NF-kappaB inhibition such as a reduced specific IgE secretion, chemokine expression and Th2 cytokine production as well as an altered eosinophilic cytoskeletal rearrangement [35,36]. Overall, As2O3 might exert its multiple anti-inflammatory action through augmentation of IkappaBalpha expression and suppression of NF-kappaB activation in the airways. This is partially in accordance with the therapeutic role of glucocorticoid-mediated NF-kappaB repression in asthma [37,38]. Interestingly, in this model of asthma, As2O3 abrogated both allergic airway inflammation and AHR in contrast with the previous report [29], suggesting a specific effect of As2O3 besides NF-kappaB suppression. Taken together, these findings not only prove an essential role of NF-kappaB-mediated airway inflammation, but also illustrate the importance of alternative signaling pathway and additional cell types in the airways, and the complicated interactions between them in dictating the pathophysiology of asthma.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 70 72 70 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 208 209 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 210 212 198 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 341 342 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 343 345 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 462 463 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 464 466 448 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 479 480 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 481 483 465 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 715 717 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 718 720 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 917 918 885 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 919 920 887 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 921 923 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 924 926 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
Our data demonstrate that a broader anti-inflammatory activity of As2O3 lies in the inhibition of NF-kappaB activation through induction of IkappaBalpha expression in the airways. Clinically, low dosage of As2O3 may have a potential benefit in treating patients with asthma, especially in those with steroid-dependent and -resistant asthma [8,13]. It is anticipated that specific inhibitors of NF-kappaB may be developed by modifying the poisonous group(s) of As2O3 and screen As2O3 analogues in the libraries of chemical compounds. Moreover, novel nondegradable IkappaBalpha mutant, namely super-repressor of NF-kappaB, may be achieved by completely deleting the phosphorylation sites of Ser32 and Ser36 residues [18,37]. This will offer promising strategies for future immunotherapy of asthma as well as the infectious, inflammatory, cancerous and autoimmune diseases associated with aberrant NF-kappaB activation [1,5,39-42].
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 366 377 <span type="species:ncbi:3704">Horseradish</span>
AHR, Airway hyperresponsiveness; ANOVA, One-way analysis of variance; APL, Acute promyelocytic leukemia; As2O3, Arsenic trioxide; ATRA, All-trans retinoic acid; BALF, Bronchoalveolar lavage fluid; ECL, Enhanced chemiluminescence; EOS, Eosinophils; ECA, EOS chemotaxis assay; ELISA, Enzyme-linked immunosorbant assay; EMSA, Electrophoretic mobility shift assay; HRP, Horseradish peroxidase; IL, Interleukin; IkappaB, Inhibitor of NF-kappaB; NF-kappaB, Nuclear factor kappaB; OVA, Ovalbumin; PBS, Phosphate-buffered saline; RANTES, Regulated upon activation, normal T cell expressed and secreted; SEM, Standard error of the mean; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel eletrophoresis; Th2, T-helper type 2.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The author(s) declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
LFZ conceived and designed the study, carried out all experiments, analyzed the data, and drafted the manuscript. YZ participated in the animal experiments, BALF cell counts, ECA, and ELISA. XFC performed the EMSA and Western blot analysis. WPX conducted the airway physiology, lung histology, and partial data analysis. AHH gave helpful advice for data analysis and interpretation. KSY coordinated most of the experiments and advised on data analysis. All authors read and approved the final manuscript.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
###xml 204 212 <span type="species:ncbi:9606">Children</span>
We thank Drs. Heng-Jiang Zhao, Jing-Xu Zhu (The Hospital of University of Pennsylvania), Ruth He and Chyze-Whee Ang for thoughtful comments, and Guang Yang, Hakon Hakonarson and Michael M. Grunstein (The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine) for critical review of the manuscript.
###end p 77
###begin p 78
This work was supported by grants from the National Youth Natural Science Foundation of China 30400191 (LFZ), National Natural Science Foundation of China 30570797 (KSY and LFZ), Key Subject of Project "135" of Jiangsu Province 20013102 (KSY), Jiangsu Provincial Administration Bureau of Traditional Chinese Medicine 9974 (KSY), and Summit Project of Jiangsu Personnel 06B035 (LFZ).
###end p 78
###begin article-title 79
###xml 96 101 <span type="species:ncbi:9606">human</span>
Effects of adenoviral gene transfer of mutated IkappaBalpha, a novel inhibitor of NF-kappaB, on human monocyte-derived dendritic cells
###end article-title 79
###begin article-title 80
T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma
###end article-title 80
###begin article-title 81
###xml 91 96 <span type="species:ncbi:9606">human</span>
Inhibition of nuclear factor-kappaB activation un-masks the ability of TNF-alpha to induce human eosinophil apoptosis
###end article-title 81
###begin article-title 82
Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma
###end article-title 82
###begin article-title 83
Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic
###end article-title 83
###begin article-title 84
Maturational differences in lung NF-kappaB activation and their role in tolerance to hyperoxia
###end article-title 84
###begin article-title 85
###xml 90 95 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide induces the expression of cellular inhibitor of apoptosis protein-2 in human macrophages
###end article-title 85
###begin article-title 86
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia
###end article-title 86
###begin article-title 87
The role of nuclear factor-kappaB in pulmonary diseases
###end article-title 87
###begin article-title 88
Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation
###end article-title 88
###begin article-title 89
###xml 112 118 <span type="species:ncbi:10090">murine</span>
Adenoviral gene transfer of the NF-kappaB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model
###end article-title 89
###begin article-title 90
Regulation of Toll-like receptor 4-induced pro-asthmatic changes in airway smooth muscle function by opposing actions of ERK1/2 and p38 MAPK signaling
###end article-title 90
###begin article-title 91
###xml 134 145 <span type="species:ncbi:10141">guinea-pigs</span>
Inhibition of nuclear factor kappaB overexpression by arsenic trioxide contributes to apoptosis of pulmonary eosinophils in asthmatic guinea-pigs
###end article-title 91
###begin article-title 92
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Role of low dosage arsenic trioxide on pulmonary dendritic cells in asthmatic mice
###end article-title 92
###begin article-title 93
###xml 104 110 <span type="species:ncbi:10090">murine</span>
CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
###end article-title 93
###begin article-title 94
Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation
###end article-title 94
###begin article-title 95
Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3
###end article-title 95
###begin article-title 96
Adenovirus-mediated overexpression of novel mutated IkappaBalpha inhibits nuclear factor kappaB activation in endothelial cells
###end article-title 96
###begin article-title 97
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Female mice are more susceptible to the development of allergic airway inflammation than male mice
###end article-title 97
###begin article-title 98
Therapeutics targeting the innate immune system
###end article-title 98
###begin article-title 99
###xml 80 85 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: role of NF-kappaB and sensitivity to glucocorticoids
###end article-title 99
###begin article-title 100
Pro-asthmatic effects and mechanisms of action of the dust mite allergen, Der p 1, in airway smooth muscle
###end article-title 100
###begin article-title 101
The IkappaB - NF-kappaB signaling module: temporal control and selective gene activation
###end article-title 101
###begin article-title 102
A novel mechanism of nuclear factor-kappaB regulation by adenoviral protein 14.7K
###end article-title 102
###begin article-title 103
Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma
###end article-title 103
###begin article-title 104
Mechanisms of persistent NF-kappaB activity in the bronchi of an animal model of asthma
###end article-title 104
###begin article-title 105
Association between IL-1beta/TNF-alpha-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle
###end article-title 105
###begin article-title 106
A critical role for NF-kappaB in GATA3 expression and TH2 differentiation in allergic airway inflammation
###end article-title 106
###begin article-title 107
NF-kappaB activation in airways modulates allergic inflammation but not hyperresponsiveness
###end article-title 107
###begin article-title 108
Asthma
###end article-title 108
###begin article-title 109
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse modle of asthma
###end article-title 109
###begin article-title 110
Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D
###end article-title 110
###begin article-title 111
Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis
###end article-title 111
###begin article-title 112
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Effector CD8+T cells mediate inflammation and airway hyper-responsiveness
###end article-title 112
###begin article-title 113
Revising the immunological theories of asthma and allergy
###end article-title 113
###begin article-title 114
The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma
###end article-title 114
###begin article-title 115
Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer
###end article-title 115
###begin article-title 116
###xml 69 74 <span type="species:ncbi:9606">human</span>
Role of p38 MAPK and NF-kappaB for chemokine release in coculture of human eosinophils and bronchial epithelial cells
###end article-title 116
###begin article-title 117
###xml 34 39 <span type="species:ncbi:9606">human</span>
Bi-directional activation between human airway smooth muscle cells and T lymphocytes: role in induction of altered airway responsiveness
###end article-title 117
###begin article-title 118
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function
###end article-title 118
###begin article-title 119
###xml 45 49 45 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP </sub>
###xml 109 113 <span type="species:ncbi:10116">rats</span>
Effects of iptakalim hydrochloride, a novel KATP channel opener, on pulmonary vascular remodeling in hypoxic rats
###end article-title 119
###begin article-title 120
CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen
###end article-title 120

